dc.contributor | Departament de Salut |
dc.date.accessioned | 2019-03-27T13:32:52Z |
dc.date.available | 2019-03-27T13:32:52Z |
dc.date.issued | 2018-09-26 |
dc.identifier.citation | Propiverina per al tractament dels símptomes urinaris en la síndrome de bufeta hiperactiva. Barcelona: Servei Català de la Salut; 2018. |
dc.identifier.uri | https://hdl.handle.net/11351/3878 |
dc.description | Propiverina; Hyperactive bladder syndrome; Urinary symptoms: |
dc.description.abstract | Hyperactive bladder syndrome (SBH) is characterized by urinary urge, with urinary incontinence (UU) of urgency or without, with absence of infection or of another obvious pathology, and that is usually associated with an increase in daytime urinary frequency and nocturia. Urgency is the distinctive symptom of SBH and it is defined as a sudden and imperative urge to urinate the urination. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.relation.ispartof | Programa d'harmonització farmacoteràpeutica, Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Bufeta - Malalties |
dc.subject | Antiespasmòdics - Ús terapèutic |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Parasympatholytics |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.subject.mesh | Urinary Bladder, Overactive |
dc.title | Propiverina per al tractament dels símptomes urinaris en la síndrome de bufeta hiperactiva |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | parasimpaticolíticos |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | evaluación de medicamentos |
dc.subject.decs | vejiga urinaria hiperactiva |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |